Objectives: This randomized.

Objectives: This randomized, double-blind, cross-over meditation evaluated the risk of bronchoconstriction with brace preparations of inhaled tobramycin in children with cystic fibrosis (CF) infected with Pseudomonas aeruginosa with and without airway hyperreactivity.

Design: Of 19 children with CF (age range, 7 to 16 years) with mild-to-moderate pulmonary disease, 10 children were at high risk (HR) for bronchospasm (family history of asthma and previous answer to bronchodilators) and 9 children were at gentle risk (LR) for bronchospasm (no family history of asthma or previous answer to bronchodilators). Two solutions of tobramycin were administered: (1) 80 mg in a 2-mL vial diluted with 2 mL of saline solution containing the preservatives phenol and bisulfites (IV preparation); and (2) 300 mg in a preservative-free preparation in a 5-mL solution. Following a bronchodilator-free period of 12 h the patients inhaled either single in kind or the other preparation in random order forward two different occasions, 2 weeks apart.

Results: Prechallenge and postchallenge springs for the LR group showed a percentage of fall in FE[Vsub1] ([DELTA]FE[V.sub.1]) of 12 [+ or -] 9% (mean [+ or -] SD) for the IV preparation, compared to 4 [+ or -] 5% for the preservative-free preparation (p = 0046) An [DELTA]FE[V.sub.1] of > 10% was seen in six of nine patients for the IV preparation and in common of nine patients for preservative-free preparation. For the HR cluster the [DELTA]FE[V.sub.1] was 17 [+ or -] 13% for the IV-preparation cluster compared to 16 [+ or -] 12% for the preservative-free dispose (p = 0.4). In this cluster equal numbers of patients (8 of 10 patients) had an [DELTA]FE[V.sub.1] > 10% after inhaling each preparation. The largest [DELTA]FE[V.sub.1] was 44% (HR cluster with the preservative-free preparation that forced the early termination of inhalation).

Conclusions: the couple preparations caused significant bronchoconstriction in the HR arrange and the preservative-containing IV preparation caused more bronchospasm in LR assign places to than the preservative-free solution. Heightened airway reactivity in children with CF places them at risk of bronchospasm from inhalation therapy.

tonic words: bronchial constriction; bronchospasm; cystic fibrosis; inhaled antibiotics; tobramycin

Abbreviations. CF = cystic fibrosis; [DELTA]FE[V.sub.1] = percentage of fall in FE[Vsub1]; HR = high risk; LR = grave risk; mOsm = milliosmole

**********

The benefits of inhaled tobramycin are well established in the ambulatory treatment of Pseudomonas aeruginosa endobronchial infection in patients with cystic fibrosis (CF) (1-3) A large, multicenter, double-blinded, controll trial (4) of intermittent treatments of inhaled tobramycin showed a significant improvement in pulmonary function and a decreased common occurrence of hospitalization. Additional benefits of inhaled tobramycin are that the aerosolized course delivers the medication to the target site of infection with relatively fewer side results and can be easily used in the hearthstone environment. To date, there has been no dose-ranging subject of attention nor has the ideal preparation of tobramycin been established in comparative studies.

Evidence suggesting inactivation of aminoglycosides in CF sputum has been used as an argument for attempting to achieve high intrabronchial concentrations of tobramycin. (5) united of the preparations of inhaled tobramycin that has been used in many studies (1267) in patients with CF is an IV form (IV preparation, 80 mg for 2-mL vial) [Eli Lilly; Toronto, in succession Canada] that contains 1.44 mg/mL sodium metabisulphite as antioxidant and 5 mg/mL of phenol as preservative. This preparation is usually diluted with 2 mL of saline solution. It has been widely used at CF clinics in a number of countries. The mostly recent large, placebo-controlled trial (4) used a preservative-free formulation of 300 mg by 5 mL. Long-term improvements in pulmonary function have been seen with the couple preparations (1,4) and short-term adverse issues of bronchoconstriction have also been observ with one as well as the other the preservative-containing solution (7-9) and with the preservative-free solution. (4) There has been no prospective reflection reporting on the risk of bronchospasm with either preparation. Furthermore, a subpopulation of patients with CF may posses inherent airway hyperreactivity, and therefore may be at more risk of bronchospasm from any inhaled solution. (10)

This thought compared potential side effects of the 80-mg IV preparation to a preservative-free solution. There were couple objectives of this study. The first was to compare the risk of bronchoconstriction associated with the inhaled IV and preservative-free preparations of tobramycin in children with CF and mild-to-moderate pulmonary disease. The other was to assess whether inherent airway hyperreactivity artificial positions any additional risk for bronchoconstriction in patients with CF inhaling the brace preparations.

MATERIALS AND METHODS

Nineteen patients with CF with mild-to-moderate pulmonary disease were chronicleed from those followed up in the CF Clinic at the Hospital for Sick Children in Toronto, Canada. All were chronically infected with P aeruginosa and were receiving 80 mg of the tobramycin solution containing preservatives diluted with 2 mL of saline solution twice daily, using a breath-enhanced nebulizer at abode (11) This is the present standard in the clinic, with the exception that albuterol is usually added to the preparation. Their ages ranged from 7 to 16 years (mean, 12 years), and they were able to perform spirometry. Patients who had a baseline percentage of predicted FE[Vsub1] of [greater than or equal to] 50% and had a previously determined bronchodilator replication were identified from our CF database. A positive bronchodilator reply was defined as either a [greater than or equal to] 12% change (12) in FE[Vsub1] from baseline forward one occasion or a answer of [greater than or equal to] 10% change in FE[Vsub1] from baseline forward three or more occasions. The bronchodilator replication was determined following the administration of 400 [micro]g of albuterol by the agency of a metered-dose inhaler using a valved holding chamber (Aerochamber; Trudell Medical Group; London, in succession Canada). Clinical histories were reviewed, and the nearness or absence of a personal or family history of atopy or asthma coupl with clinical symptoms that improved with bronchodilators was assessed. alone those patients who satisfied the two the spirometric and the clinical criteria, eg appearance or absence of the above, were approached to participate in the investigation No subject was approached if there was any suggestion of allergic bronchopulmonary aspergillosis. Patients were classified into sum of two units subgroups. The first group (n = 10) labeled as a high-risk (HR) cluster for bronchospasm, had the combination of a positive reply to bronchodilators and a history suggestive of asthma. The other group (n = 9), labeled as a low-risk (LR) dispose for bronchospasm, did not posses any of these characteristics. A comprehensive chart review for all patients in the two groups was done to make secure that all the clinical criteria were met Patients were exclud if they had a pulmonary exacerbation requiring a change in antibiotic treatment, either as inpatients or outpatients, within 4 weeks of note into the study. The ethics committee of the hospital approved the investigation and informed consent was obtained from all patients and their parents before participating.

...